Foreign pharmaceutical firms are eyeing the world’s second largest market for profit opportunities as well as innovative assets.
The booth of pharmaceutical company Eli Lilly in a section for 'Public Health and Epidemic Prevention' at the 3rd China International Import Expo in Shanghai, November 6, 2020. Credit: Zhang Yuwei/Xinhua via Getty Images
While many foreign businesses are scaling back in China, U.S. pharmaceutical giant Eli Lilly is going against the grain with a string of new investments.
Eli Lilly officials pose during an expansion ceremony held at the company's site in Suzhou, October 11, 2024. Credit: Eli Lilly
The Indianapolis-based company is plowing $212 million to expand its plant in Suzhou, it announced on WeChat last month. The expansion, which will bring its total investment since 1996 in the southeastern city t
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from Andrew Peaple.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
If Xi Jinping is becoming more preoccupied with internal politics, it could lead to a period of relative calm in China’s relations with the United States.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OKPrivacy policy
